Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Concurrent Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib in Patients With Inoperable Stage III Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN06-107

NCT00417248 is registered in ClinicalTrials.gov with Nasser Hanna, M.D. as lead sponsor.

NCT NCT00417248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00417248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Concurrent Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib in Patients With Inoperable Stage III Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN06-107
Lead sponsor
Nasser Hanna, M.D.
Phase
Phase 1/2
Overall status
Terminated
Start date
June 30, 2007
Completion date
April 30, 2008
Enrollment
8 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer